Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing treatments for addiction and related disorders. The company’s core business centers on addressing opioid use disorder through a portfolio of branded pharmaceuticals and delivery systems designed to support long-term recovery. Indivior’s therapies are aimed at improving patient outcomes by reducing withdrawal symptoms and lowering the risk of relapse.
The company’s flagship product, Suboxone®, is a buprenorphine-naloxone sublingual film approved for the treatment of opioid dependence. In addition to Suboxone, Indivior markets Sublocade®, an extended-release buprenorphine injection, and offers generic formulations of medication-assisted therapies. Its ongoing research and development efforts encompass next-generation formulations and novel compounds intended to enhance safety, efficacy and patient adherence.
Indivior was established in July 2014 following a spin-off from Reckitt Benckiser Group PLC, with its corporate headquarters in Slough, United Kingdom, and its U.S. headquarters in Richmond, Virginia. Since its inception, the company has expanded its commercial reach to serve patients and healthcare providers across North America, Europe, Australia and select markets in Asia. Indivior maintains manufacturing and distribution capabilities in multiple geographies to support global supply chains.
The leadership team is led by Chief Executive Officer Mark Crossley, who brings extensive experience in specialty pharmaceuticals and global operations. Under his direction, Indivior continues to invest in clinical programs and strategic partnerships aimed at advancing its pipeline. The company’s management emphasizes a patient-centric approach, collaborating with governments, payers and advocacy groups to improve access to evidence-based addiction treatments worldwide.
AI Generated. May Contain Errors.
